Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Tennessee Federal Judge Won’t Dismiss Jaw Injury Cases

By Pharmaceutical Processing | March 9, 2010

NASHVILLE, Tenn., (AP) — A federal judge refused to dismiss 40 lawsuits against a Swedish-based pharmaceutical company accused of failing to warn patients that two of its drugs can cause severe jaw deterioration.

U.S. District Judge Todd Campbell’s ruling last week was the latest blow to Novartis Corp., which is facing lawsuits from hundreds of patients around the country over its bone-strengthening drugs Aredia and Zometa. The 40 cases from people treated with the drugs in Florida represent a portion of the more than 600 cases against Novartis in the U.S. District Court in Nashville. About 150 more cases are being handled by a state court in New Jersey.

Campbell’s decision clears the way for the 40 cases to go to trial.

“This was another try by Novartis to try to get a number of these cases knocked out,” said John Vecchione, a Fairfax-Va., -based attorney who represents a number of plaintiffs in the case. “By and large, they’ve failed with a broad brush to dismiss these cases.”

Trials are set to begin later this year in districts around the country.

The only case that’s gone to trial so far resulted in a $3.2 million jury verdict in October for a Missoula, Mont., woman with lymphoma who sued the drug maker, claiming she developed severe dental and jaw-related problems after taking Zometa.

A spokeswoman for Novartis said in an e-mail that the company did not comment on pending litigation. It has denied in court documents that the drugs were to blame for a condition called osteonecrosis of the jaw.

Zometa and Aredia were approved by the FDA to strengthen bones in patients with certain types of cancers. The lawsuits claim the drugs cause portions of the jawbone to die.

“We’ve had clients who’ve actually had their entire lower jaw removed,” said Patrick Flynn, a Brentwood-Tenn., lawyer who represents a number of plaintiffs. “There’s constant pain and infection that attend this kind of condition.”

The Food and Drug Administration approved Aredia in 1991 and Zometa in 2001.

An agency spokeswoman said in an e-mail that the FDA held a public meeting in March 2005 to discuss issues with osteonecrosis of the jaw involving the drugs. She said a warning about the possible side effect was later added to the prescribing information.

In spite of the side effects, one doctor says the drugs can greatly increase the quality of life for people with cancers involving the bone because they help reduce fractures and pain.

“In most patients, they’re quite a bit of a benefit,” said Dr. Sal Vasireddy, an associate professor with the University of Tennessee Health Science Center.

Still, he says, patients considering taking either drug need to talk with their doctors because necrosis of the jaw is considered a serious complication that could impede cancer treatment.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE